A Phase 3, Open Label, Randomized, Parallel, 26 Week Treatment Study Comparing LY2605541 With Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti Hyperglycemia Medications in Asian Insulin Naive Patients With Type 2 Diabetes Mellitus
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Insulin peglispro (Primary) ; Antihyperglycaemics; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 12 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Mar 2014 Planned End Date changed from 1 May 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.